Sahajanand Medical Technologies Limited’s Initial Public Offering of Equity Shares to Open on Thursday, October 15, 2026, Price Band Set at Rs 327 – Rs 344 Per Equity Share

Mumbai, October 12, 2026: Sahajanand Medical Technologies Limited (“Company”) has fixed the price band at Rs 327/- to Rs 344/- per Equity Share for its initial public offering of Equity Shares.

The Initial Public Offering (“IPO” or “Offer”) of the Company will open on Thursday, October 15, 2026, for subscription and close on Monday, October 19, 2026.

Investors can bid for a minimum of 43 Equity Shares and in multiples of 43 Equity Shares thereafter.

Equity shares outstanding as on date 101,646,778 Equity Shares.

The IPO comprises an offer for sale of up to 13,822,116 Equity Shares of face value of Re 1 each by the Company’s Promoter, Shree Hari Trust; a member of the Promoter Group, Dhirajkumar Savjibhai Vasoya; and the following Investor Selling Shareholders: Samara Capital Markets Holding Limited, Kotak Pre-IPO Opportunities Fund and NHPEA Sparkle Holding B.V.

The offer includes a reservation of up to 250,000 Equity Shares for subscription by eligible employees (the “Employee Reservation Portion”). The Offer less the Employee Reservation Portion is referred to as the “Net Offer”.

The Offer is being made through the book-building process, in line with SEBI ICDR Regulations, with not more than 50% of the Net Offer reserved for Qualified Institutional Buyers (QIBs), not less than 15% of the Net Offer for Non-Institutional Bidders (NIBs), and not less than 35% of the Net Offer for Retail Individual Bidders (RIBs).

The Company was formed as a partnership firm in 1999, and thereafter incorporated as a joint stock company in 2001. The Company is a Class III and Class C/D medical devices company with a portfolio of technologically advanced medical devices across vascular and structural heart intervention. According to the report titled “Independent Market Research on Cardiovascular Devices Market” dated September 30, 2026, prepared and released by Frost & Sullivan (the “F&S Report”), the Company was the first in the world to receive a CE certification for a DES with a biodegradable polymer- based paclitaxel-eluting stent (Infinnium). Over the years, the Company has introduced several innovative products, driven by its focus on research and development and precision manufacturing capabilities enabling it to deliver quality products backed by clinical data, with a presence across 65 countries including India in the three months ended June 30, 2026 and 77 countries including India in Fiscal 2026.

It is a R&D-driven company engaged in the development of Class III and Class C/D medical devices, with an emphasis on vascular intervention (VI) and structural heart (SH). Its portfolio of (i) VI products includes coronary intervention products such as coronary stents and coronary balloons, (ii) SH products include TAVI and occluders, and (iii) Others including its own brand of renal stents, peripheral DCBs and other trading products.

According to the F&S Report, the Company has a leading market share in the drug eluting stents (DES) market in India, with a market share of nearly 25% in Fiscal 2026 of the total DES sales volume in India. Further, according to the F&S Report, it is among the top five companies in terms of market share by sales volume of DES in Germany, Spain, Poland and Brazil, as of March 31, 2026. Additionally, it is among the top five companies in terms of market share by sales volume of occluders in Thailand, South Korea and India, as of March 31, 2026.

The Company’s strategy centres on continuous innovation, expanding its product portfolio, enhancing existing products, and exploring new technologies to address evolving clinical and market needs. As of June 30, 2026, it has two R&D centers – one in India and another in Thailand, supported by a team of 156 professionals (including four consultants), each with experience in biomedical engineering, technology development, and clinical research.

Additionally, the Company has built a robust intellectual property portfolio, with 119 patents granted globally, 78 more patent applications in the pipeline, and five design registrations in India as of the date of the Red Herring Prospectus.

The Company’s R&D efforts have resulted in an industry first and product enhancements. Additionally, the Company has developed a patented AVDC system for its Hydra TAVI, improving deliverability, after the acquisition of Vascular Innovations. The next generation of AVDC received CE approval in Fiscal 2026.

The Company has built a strong clinical foundation for its flagship products – Supraflex Cruz, Hydra, Sironity Drug-coated PTCA Balloon, Pipit and Cocoon, supported by 75 clinical studies (comprising 66 completed studies and 09 ongoing studies), as of June 30, 2026, across diverse geographies and patient populations. The Company’s commitment to quality is reflected in its distinction as one of the few Indian medtech companies with results of key clinical trials on products published in top-tier journals such as The Lancet (impact factor 109) and NEJM (impact factor 84.5), according to the F&S Report. Further, Supraflex Cruz has been shown to offer better deliverability and clinical outcomes than the DES of leading competitors, while Hydra and Cocoon stand out among the Company’s peers for their advanced features and safety profiles, according to the F&S Report.

The Company has marketed its products in 77 countries including India in Fiscal 2026, through a mix of direct, hybrid, and distributor-led models, adapting to local regulatory and market conditions. In India, through its hybrid model, it caters to large hospitals, including Narayana Hrudayalaya Limited. In Europe, it has direct operations in Germany, Spain, France and UK, successfully navigating complex regulatory and procurement environments.

As on the date of the Red Herring Prospectus, the Company and its Subsidiaries have three manufacturing facilities, two located in India and one in Thailand.

The Company’s revenue from operations was Rs 3,516.69 million during the three months’ period ended June 30, 2026, and it had a profit after tax of Rs 150.87 million during this period.

The Company’s revenue from operations was Rs 12,105.04 million during FY26 as compared to Rs 10,248.79 million during FY25. The Company’s profit after tax was Rs 690.82 million during FY26 as compared to Rs 251.52 million during FY25.

Motilal Oswal Investment Advisors Limited, Avendus Capital Private Limited, HSBC Securities and Capital Markets (India) Private Limited and Nuvama Wealth Management Limited are the book-running lead managers to the Offer, and MUFG Intime India Private Limited is the registrar to the Offer.

The equity shares are proposed to be listed on NSE and BSE.